Needham analyst Michael Matson maintained a Buy rating on Haemonetics (HAE – Research Report) today and set a price target of $104.00. The ...

Haemonetics (HAE) announced updates to its Executive Leadership team. Frank Chan, Ph.D. will join Haemonetics as Executive Vice President, COO on April 7, and Roy Galvin has been appointed as the ...

BOSTON, March 3, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes ...